ATL’s unique approach targets the host's immune system (not the infectious organism) thereby avoiding the development of AMR (anti-microbial resistance). This is achieved by modulating an animal's natural immunity thus helping it to combat infection naturally. Our platform technology has many potential applications, but within ATL’s first target market (the animal feed sector) our approach is unique and potentially game-changing.
Modern farming systems aim to produce the highest quality food at maximum volume and lowest cost. To achieve these objectives farmers actively manage the health and wellbeing of livestock to reduce disease. Employing modern husbandry techniques, farmers can prevent many diseases and infections that would otherwise cause distress to their animals and compromise the commercial viability of their herd or flock.
Sourced and isolated from plants that we have exhaustively tested
Demonstrated to have activity in animals when dosed orally
Aramune is safe and is not associated with any of the adverse effects of endotoxin lipopolysaccharide
Aramune is sustainably produced from a variety of plant sources (some are native wildflowers in the UK) that are also grown specifically as a resource for pollinator species such as bees and butterflies
Even when used at doses that are greater than 10 times its maximum activity, Aramune is not cytotoxic in animals or humans
Aramune Technologies Ltd (ATL) was incorporated in February 2021 as a Queen's University Belfast (QUB) spin-out company. The intellectual property has been exclusively licensed by QUB to ATL. In addition, the company continues to develop new IP and know-how related to the commercial extraction of plant compounds and the field cultivation of ‘source’ plant species.
Thank you for your interest in Aramune! If you have questions, comments, or would like to talk about our products and technology, please contact us and we’ll get back to you as soon as possible.